AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Haematology Business Unit, emphasized Imfinzi’s potential to transform LS-SCLC treatment, noting that it is now the only ...